Apremilast for the off-label treatment of lichenoid and interface dermatoses - 10/10/20
Doi : 10.1016/j.jaad.2020.05.112
Surya Ravichandran, BS a, Meenal K. Kheterpal, MD b, ⁎ 
a Duke University School of Medicine, Duke University Medical Center, Durham, North Carolina
b Department of Dermatology, Duke University Medical Center, Durham, North Carolina
∗Reprint requests: Meenal K. Kheterpal, MD, Department of Dermatology, Duke University Medical Center, 40 Duke Medicine Circle, Durham, NC 27710-4000Department of DermatologyDuke University Medical Center40 Duke Medicine CircleDurhamNC27710-4000
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Reviewed and approved by the Duke University IRB (Pro00100765). |
© 2020
Publié par Elsevier Masson SAS.
Vol 83 - N° 5
P. 1489-1491 - novembre 2020 Retour au numéro
Article précédent
- Tofacitinib in the treatment of lichen planopilaris: A retrospective review
- John Plante, Chelsea Eason, Alan Snyder, Dirk Elston
- Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia
- Abhijeet Kumar Jha, Sidharth Sonthalia, MD Zeeshan, Keshavamurthy Vinay
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?